Physician profile
Thomas Ein
NPI 1104807791
$2,832.83
in general payments reported to CMS, 2019-2025
32 companies · $292 in 2025
The $292 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $552 · 2020: $251 · 2021: $360 · 2022: $508 · 2023: $597 · 2024: $272 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,161.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $589.97 | 2019-2023 | |
| Astellas Pharma US INC | $264.75 | 2023-2025 | Veozah, Myrbetriq |
| Daiichi Sankyo INC. | $221.90 | 2021-2023 | Injectafer |
| Pfizer INC. | $168.21 | 2019-2025 | |
| Aspira Women'S Health INC | $159.22 | 2019-2024 | Ova1 |
| Hologic Sales and Service, LLC | $159.16 | 2021-2025 | Aptima, Novasure, Myosure Tissue Removal Device |
| Amag Pharmaceuticals, INC. | $117.48 | 2019 | |
| Therapeuticsmd, INC. | $111.06 | 2019-2022 | |
| Coopersurgical, INC. | $109.20 | 2020-2023 | Summit Doppler, Mara Console, Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $104.16 | 2019-2023 | |
| Renovia INC | $102.52 | 2019 | |
| Millicent US INC | $85.52 | 2019-2025 | Femlyv, Intrarosa, Femring |
| Shield Therapeutics INC | $84.69 | 2023-2024 | Accrufer |
| Merck Sharp & Dohme LLC | $68.88 | 2019-2025 | Gardasil 9 |
| Sumitomo Pharma America, INC. | $60.94 | 2023-2025 | Gemtesa, Myfembree |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $49.55 | 2023 | |
| Myovant Sciences INC. | $46.78 | 2021 | |
| Mission Pharmacal Company | $44.42 | 2019-2020 | |
| Exeltis, USA INC. | $32.73 | 2022-2024 | Slynd |
| Avion Pharmaceuticals | $29.95 | 2021-2023 | Balcoltra |
| Evofem Biosciences, INC. | $28.71 | 2022 | |
| Organon LLC | $26.53 | 2024 | |
| Trevena, INC. | $25.76 | 2023 | Olinvyk |
| Cumberland Pharmaceuticals, INC. | $23.15 | 2021 | |
| Optumhealth Care Solutions, LLC | $22.43 | 2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Roche Diagnostics Corporation | $22.00 | 2019 | |
| Amgen INC. | $19.17 | 2022 | |
| Mylan Pharmaceuticals INC. | $16.40 | 2022 | |
| Agile Therapeutics, INC. | $14.64 | 2022 | |
| Mckesson Patient Care Solutions INC. | $11.76 | 2019 | |
| Meditrina | $11.19 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Ein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.